SCHRÖDINGER, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.83 USD | -0.68% |
|
-0.91% | -38.99% |
| May. 13 | Ajax Therapeutics, Inc. announced that it has received $95 million in funding from a group of investors | CI |
| May. 07 | Ansys Partners With Schrodinger to Accelerate Materials Development | MT |
Financials (USD)
| Sales 2024 * | 205M | Sales 2025 * | 278M | Capitalization | 1.6B |
|---|---|---|---|---|---|
| Net income 2024 * | -199M | Net income 2025 * | -198M | EV / Sales 2024 * | 6.09 x |
| Net cash position 2024 * | 349M | Net cash position 2025 * | 317M | EV / Sales 2025 * | 4.6 x |
| P/E ratio 2024 * |
-8.07
x | P/E ratio 2025 * |
-8.3
x | Employees | 867 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.31% |
More Fundamentals
* Assessed data
More news
Latest transcript on Schrödinger, Inc.
More recommendations
More press releases
More news
| 1 day | -0.86% | ||
| 1 week | -0.59% | ||
| Current month | -10.13% | ||
| 1 month | -10.35% | ||
| 3 months | -30.16% | ||
| 6 months | -29.91% | ||
| Current year | -38.80% |
1 week
21.66
23.37
1 month
21.6626.75
Current year
21.6636.13
1 year
20.7659.24
3 years
15.8579.75
5 years
15.85117.00
10 years
15.85117.00
| Managers | Title | Age | Since |
|---|---|---|---|
Frank Taffy
FOU | Founder | - | 20-12-31 |
Ramy Farid
CEO | Chief Executive Officer | 59 | 01-12-31 |
Geoffrey Porges
DFI | Director of Finance/CFO | 63 | 22-08-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Arun Oberoi
BRD | Director/Board Member | 70 | 22-05-16 |
Michael Lynton
CHM | Chairman | 64 | 17-12-31 |
Gary Ginsberg
BRD | Director/Board Member | 61 | 20-04-29 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.98% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 21.85 | -0.59% | 322 194 |
| 24-05-24 | 21.98 | +0.73% | 445,447 |
| 24-05-23 | 21.82 | -3.66% | 558,785 |
| 24-05-22 | 22.65 | +2.77% | 860,885 |
| 24-05-21 | 22.04 | -2.48% | 604,476 |
Delayed Quote Nasdaq, May 28, 2024 at 02:20 pm EDT
More quotes
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor). Its software was used by researchers around the world at more than 1,760 academic institutions.
Sector
Software
Calendar
2024-06-05
- Jefferies Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
21.98
USD
Average target price
36.5
USD
Spread / Average Target
+66.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -38.80% | 1.6B | |
| +14.02% | 3,197B | |
| +14.69% | 89.6B | |
| +8.57% | 80.08B | |
| -13.37% | 55.52B | |
| +22.60% | 46.79B | |
| +32.68% | 46.34B | |
| -30.75% | 43.95B | |
| +69.93% | 41.34B | |
| -3.31% | 26.5B |
- Stock Market
- Equities
- SDGR Stock
